A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab 140 mg subcutaneously every 2 weeks. Treatment-emergent changes in lipids and lipoproteins were long-lasting, and the medication was well tolerated by the patient in the long-term. Unexpectedly, after 2 years of continuous treatment with evolocumab, serum lipids increased, apparently without any reasonable explanation. During the follow-up visit, the patient was found to have habitually injected evolocumab into his right thumb instead of into the appropriate injection sites (i.e., abdomen, thighs or upper arms) after turning the injector upside down.

Fogacci F, B.C. (2021). Sudden Fall in the Lipid- Lowering Effect of Evolocumab: The Butler Is Not Always Guilty. MEDICINA, 57(8), 1-4 [10.3390/medicina57090857].

Sudden Fall in the Lipid- Lowering Effect of Evolocumab: The Butler Is Not Always Guilty

Borghi C
Secondo
Writing – Review & Editing
;
Di Micoli A;Cicero AFG
Ultimo
Supervision
2021

Abstract

A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab 140 mg subcutaneously every 2 weeks. Treatment-emergent changes in lipids and lipoproteins were long-lasting, and the medication was well tolerated by the patient in the long-term. Unexpectedly, after 2 years of continuous treatment with evolocumab, serum lipids increased, apparently without any reasonable explanation. During the follow-up visit, the patient was found to have habitually injected evolocumab into his right thumb instead of into the appropriate injection sites (i.e., abdomen, thighs or upper arms) after turning the injector upside down.
2021
Fogacci F, B.C. (2021). Sudden Fall in the Lipid- Lowering Effect of Evolocumab: The Butler Is Not Always Guilty. MEDICINA, 57(8), 1-4 [10.3390/medicina57090857].
Fogacci F, Borghi C, Di Micoli A, Cicero AFG
File in questo prodotto:
File Dimensione Formato  
Fogacci F_Sudden fall in the lipid lowering_Medicina 2021.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 539.95 kB
Formato Adobe PDF
539.95 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/899652
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact